Pulmonary Arterial Hypertension News and Research RSS Feed - Pulmonary Arterial Hypertension News and Research

Pulmonary arterial hypertension (PAH) is a condition involving high blood pressure and structural changes in the walls of the pulmonary arteries, which are the blood vessels that connect the right side of the heart to the lungs. Affecting people of all ages and ethnic backgrounds - but most commonly found in young women of child-bearing years - the disease has historically been chronic and incurable, with a poor survival rate. PAH is often not diagnosed in a timely manner because its early symptoms can be confused with those of many other pulmonary and respiratory conditions. Symptoms include shortness of breath, extreme fatigue, dizziness, fainting, swollen ankles and legs and chest pain (especially during physical activity). With proper diagnosis, there are currently several therapies to alleviate symptoms and improve quality of life for PAH patients. The key is to find a PAH specialist and pursue immediate treatment.
Ambrisentan avoids sildenafil drug interaction in PAH patients

Ambrisentan avoids sildenafil drug interaction in PAH patients

Sildenafil may be better given to pulmonary arterial hypertension patients in combination with ambrisentan than with bosentan, study findings suggest. [More]
BMPR2 mutations affect outcomes of PAH patients

BMPR2 mutations affect outcomes of PAH patients

Mutations in the bone morphogenetic protein receptor type II gene affect not only the risk of developing pulmonary arterial hypertension but also the severity and outcomes of the disease, shows a meta-analysis of individual patient data. [More]
Arrhythmias worth treating in PAH patients

Arrhythmias worth treating in PAH patients

Supraventricular arrhythmias are common in patients with pulmonary arterial hypertension but can be successfully managed with standard treatments, a study shows. [More]
Selexipag reduces clinical events in PAH patients

Selexipag reduces clinical events in PAH patients

Selexipag, alone or in combination with other classes of pulmonary arterial hypertension medication, reduced the composite rate of disease complications and deaths among patients in a phase III trial. [More]
New blood biomarkers could lead to better evaluation of treatment for patients with PAH

New blood biomarkers could lead to better evaluation of treatment for patients with PAH

New blood biomarkers reflecting vasoreactivity in lung blood vessels of patients with heart- and lung disease, can lead to simplified diagnostics and better evaluation of treatment for patients with the condition pulmonary arterial hypertension (PAH). [More]
Selexipag holds promise for treatment of pulmonary hypertension

Selexipag holds promise for treatment of pulmonary hypertension

Living with pulmonary arterial hypertension is challenging, but the chore of treating the rare heart disease may change following promising clinical trial data to be published in the Dec. 24 issue of the New England Journal of Medicine. [More]
Cardiome files NDS with Health Canada's TPD for approval of intravenous vernakalant

Cardiome files NDS with Health Canada's TPD for approval of intravenous vernakalant

Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced the filing of a New Drug Submission (NDS) with Health Canada's Therapeutic Products Directorate (TPD) seeking Canadian approval of intravenous vernakalant for the rapid conversion of recent onset atrial fibrillation (AF) to sinus rhythm in adults with AF for up to 7 days. [More]
FDA approves Uptravi tablets to treat adults with pulmonary arterial hypertension

FDA approves Uptravi tablets to treat adults with pulmonary arterial hypertension

On December 21, the U.S. Food and Drug Administration approved Uptravi (selexipag) tablets to treat adults with pulmonary arterial hypertension (PAH), a chronic, progressive, and debilitating rare lung disease that can lead to death or the need for transplantation. [More]
RV glucose metabolism changes associated with RV function

RV glucose metabolism changes associated with RV function

The rate of myocardium glucose utilisation in the right ventricle correlates with its function and could be used to monitor treatment effects in patients with pulmonary arterial hypertension, findings indicate. [More]

Early promise for pulmonary artery denervation in PAH patients

Pulmonary artery denervation is feasible and may reduce pulmonary arterial pressure in patients with pulmonary arterial hypertension, phase II findings suggest. [More]
Right atrial function could be prognostic in PAH

Right atrial function could be prognostic in PAH

Right atrial function is impaired in patients with pulmonary arterial hypertension and may indicate right ventricular overload and failure, research suggests. [More]
Sildenafil drug improves insulin sensitivity in people at risk for diabetes

Sildenafil drug improves insulin sensitivity in people at risk for diabetes

The drug sildenafil, sold as Viagra and other brand names, improves insulin sensitivity in people at risk for diabetes, researchers at Vanderbilt University Medical Center reported today. [More]

Haemodynamic variables may distinguish pre- from post-capillary PH

Researchers have identified the haemodynamic variables that best distinguish between patients with idiopathic pulmonary arterial hypertension and isolated post-capillary pulmonary hypertension. [More]
Patient-related outcome shows strong link to survival in PAH

Patient-related outcome shows strong link to survival in PAH

Health-related quality of life is strongly associated with survival in patients with pulmonary arterial hypertension, making it a reasonable target for treatment, study findings suggest. [More]
Pathophysiological biomarkers predict PAH prognosis

Pathophysiological biomarkers predict PAH prognosis

Researchers have identified three biomarkers that signify an increased risk of death or requirement for lung transplantation in patients with pulmonary arterial hypertension. [More]
CV risk assessment essential for CML TKI trial design

CV risk assessment essential for CML TKI trial design

The risk and impact of cardiovascular adverse events in long-term users of tyrosine kinase inhibitors for chronic myeloid leukaemia is highlighted in a review published in the Journal of Clinical Oncology. [More]
Algorithm reduces PAH screening costs in systemic sclerosis patients

Algorithm reduces PAH screening costs in systemic sclerosis patients

The Australian Scleroderma Interest Group has derived a screening algorithm for pulmonary arterial hypertension in patients with systemic sclerosis that saves costs by reducing the need for transthoracic echocardiography and right heart catheterisation. [More]
6-minute walk ‘not an accurate surrogate’ in systemic sclerosis-associated PAH

6-minute walk ‘not an accurate surrogate’ in systemic sclerosis-associated PAH

The 6-minute walk distance of patients with systemic sclerosis-associated pulmonary arterial hypertension is not a suitable marker for tracking treatment-related haemodynamic changes, say researchers. [More]
Scientists compile complete genetic information of people affected by PAH

Scientists compile complete genetic information of people affected by PAH

The genetic architecture of a debilitating and potentially fatal vascular disease has for the first time been detailed in its entirety, providing clinicians with the comprehensive data needed to improve diagnosis and deliver more personalised patient care. [More]
Amgen gets positive CHMP opinions for Kyprolis (carfilzomib) and BLINCYTO (blinatumomab)

Amgen gets positive CHMP opinions for Kyprolis (carfilzomib) and BLINCYTO (blinatumomab)

"We are pleased to receive positive CHMP opinions for Kyprolis and BLINCYTO as this is an important step in providing new treatment options for patients in Europe with rare forms of cancer," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. [More]
Advertisement